{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:11:05Z","timestamp":1790251865961,"version":"4.1.0"},"reference-count":52,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2005,9,30]],"date-time":"2005-09-30T00:00:00Z","timestamp":1128038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2005,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Adalimumab, a fully human, anti\u2013tumor necrosis factor monoclonal antibody, was evaluated for its safety and efficacy compared with placebo in the treatment of active psoriatic arthritis (PsA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with moderately to severely active PsA and a history of inadequate response to nonsteroidal antiinflammatory drugs were randomized to receive 40 mg adalimumab or placebo subcutaneously every other week for 24 weeks. Study visits were at baseline, weeks 2 and 4, and every 4 weeks thereafter. The primary efficacy end points were the American College of Rheumatology 20% improvement (ACR20) response at week 12 and the change in the modified total Sharp score of structural damage at week 24. Secondary end points were measures of joint disease, disability, and quality of life in all patients, as well as the severity of skin disease in those patients with psoriasis involving at least 3% of body surface area.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At week 12, 58% of the adalimumab\u2010treated patients (87 of 151) achieved an ACR20 response, compared with 14% of the placebo\u2010treated patients (23 of 162) (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). At week 24, similar ACR20 response rates were maintained and the mean change in the modified total Sharp score was \u22120.2 in patients receiving adalimumab and 1.0 in those receiving placebo (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). Among the 69 adalimumab\u2010treated patients evaluated with the Psoriasis Area and Severity Index (PASI), 59% achieved a 75% PASI improvement response at 24 weeks, compared with 1% of the 69 placebo\u2010treated patients evaluated (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). Disability and quality of life measures were also significantly improved with adalimumab treatment compared with placebo. Adalimumab was generally safe and well\u2010tolerated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adalimumab significantly improved joint and skin manifestations, inhibited structural changes on radiographs, lessened disability due to joint damage, and improved quality of life in patients with moderately to severely active PsA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.21306","type":"journal-article","created":{"date-parts":[[2005,9,30]],"date-time":"2005-09-30T14:49:55Z","timestamp":1128091795000},"page":"3279-3289","source":"Crossref","is-referenced-by-count":785,"title":["Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double\u2010blind, randomized, placebo\u2010controlled trial"],"prefix":"10.1002","volume":"52","author":[{"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Ritchlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Ruderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge D.","family":"Steinfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest H.S.","family":"Choy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Ory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee J.","family":"Perdok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,9,30]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"AdamsPF HendershotGE MaranoMA.Current estimates from the National Health Interview Survey 1996. National Center for Health Statistics;1999. Vital Health Stat 10(200)."},{"key":"e_1_2_6_3_2","first-page":"1247","article-title":"The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982\u20101991","volume":"27","author":"Shbeeb M","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_6_4_2","first-page":"511","article-title":"Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis","volume":"53","author":"Leonard DG","year":"1978","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_6_5_2","unstructured":"SalonenSH.The EUROPSO psoriasis patient study: treatment history and satisfaction reported by 17 990 members of European psoriasis patient associations. Proceedings of the Spring Symposium of the European Academy of Dermatology and Venereology. Malta;2003."},{"key":"e_1_2_6_6_2","article-title":"Epidemiology of psoriatic arthritis in the United States population","author":"Gelfand JM","journal-title":"J Am Acad Dermatol."},{"key":"e_1_2_6_7_2","first-page":"233","volume-title":"Primer on the rheumatic diseases","author":"Boumpas DT","year":"2001"},{"key":"e_1_2_6_8_2","first-page":"809","article-title":"Longitudinal study of clinical and radiological progression in psoriatic arthritis","volume":"17","author":"Gladman DD","year":"1990","journal-title":"J Rheumatol"},{"key":"e_1_2_6_9_2","first-page":"127","article-title":"Psoriatic arthritis: an analysis of 220 patients","volume":"62","author":"Gladman DD","year":"1987","journal-title":"Q J Med"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.119669"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000212"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20253"},{"key":"e_1_2_6_13_2","first-page":"518","article-title":"Highly increased levels of tumor necrosis factor\u2010\u03b1 and other proinflammatory cytokines in psoriatic arthritis synovial fluid","volume":"24","author":"Partsch G","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1994.tb06244.x"},{"key":"e_1_2_6_15_2","first-page":"149","volume-title":"Medical immunology","author":"Oppenheim JJ","year":"1999"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.22-2-144"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI11176"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115480"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02530-7"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.2.218"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"issue":"9","key":"e_1_2_6_23_2","first-page":"S617","article-title":"Infliximab significantly improves joint and skin involvement in psoriatic arthritis to a substantial extent and irrespective of baseline joint involvement or MTX use: analysis of clinical response from the IMPACT2 trial","volume":"50","author":"Kavanaugh A","year":"2004","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020719"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10697"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20217"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.013052"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780281203"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780391210"},{"key":"e_1_2_6_31_2","first-page":"789","article-title":"The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales","volume":"9","author":"Fries JF","year":"1982","journal-title":"J Rheumatol"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"e_1_2_6_33_2","first-page":"232","article-title":"Linking outcomes management to quality\u2010of\u2010life measurement","volume":"11","author":"Cella D","year":"1997","journal-title":"Oncology"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107263450403"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100670170004"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(05)80060-9"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/29.1.46"},{"issue":"1","key":"e_1_2_6_41_2","first-page":"403","article-title":"Preliminary data from a study of adalimumab in the treatment of psoriatic arthritis","volume":"63","author":"Ritchlin C","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"e_1_2_6_42_2","first-page":"S611","article-title":"Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis with and without PsA","volume":"50","author":"Menter MA","year":"2004","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030409"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710093371502"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28674"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.05.010"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10683"},{"issue":"9","key":"e_1_2_6_48_2","first-page":"S189","article-title":"Radiographic inhibition of structural damage sustained in patients with long\u2010standing rheumatoid arthritis following 3 years of treatment with adalimumab (HUMIRA) plus methotrexate","volume":"50","author":"Keystone EC","year":"2004","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_49_2","first-page":"4096","article-title":"Early treatment of rheumatoid arthritis (RA) with adalimumab (HUMIRA) plus methotrexate vs. adalimumab alone or methotrexate alone: the Premier study","volume":"50","author":"Breedveld FC","year":"2004","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15640-7"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(05)70361-6"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.006775"},{"issue":"3","key":"e_1_2_6_53_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jaad.2004.10.024","article-title":"Long\u2010term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis","volume":"52","author":"Langley R","year":"2005","journal-title":"J Am Acad Dermatol"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.21306","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.21306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T02:51:01Z","timestamp":1696992661000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.21306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,30]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["10.1002\/art.21306"],"URL":"https:\/\/doi.org\/10.1002\/art.21306","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,30]]}}}